SUFENTANYL
Liver Dysfunction
Tang-Du HospitalSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Liver Dysfunction cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Omeprazole Tehran University of Medical Sciences | Phase 2 | B |
Amoxicillin Tehran University of Medical Sciences | Phase 2 | B |
Azithromycin Tehran University of Medical Sciences | Phase 2 | B |
BISMUTH SUBCITRATE Tehran University of Medical Sciences | Phase 2 | B |
RAMIFENTANYL Tang-Du Hospital | Phase 2 | CCC |
View all 18 →
Same molecule, other indications
SUFENTANYL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →